Unknown PHASE1 INTERVENTIONAL 1-arm NCT02842138

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting CD19 in Patients With Relapsed or Refractory B-cell Lymphoma

Sponsor: Marino Biotechnology Co., Ltd.

Conditions B-cell Lymphoma

Interventions autologous anti-CD19 CAR T cells

Updated 9 times since 2017 Last updated: Feb 21, 2019 Started: Jun 30, 2016 Primary completion: Feb 28, 2018 Completion: Aug 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on B-cell Lymphoma, this trial is ongoing. The trial is conducted by Marino Biotechnology Co., Ltd. and has accumulated 9 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1
Mar 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE1
Mar 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marino Biotechnology Co., Ltd.
Peking University

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China